Results 241 to 250 of about 47,774 (288)

The delivery of antisense therapeutics

Advanced Drug Delivery Reviews, 2000
Antisense oligonucleotides, ribozymes and DNAzymes have emerged as novel, highly selective inhibitors or modulators of gene expression. Indeed, their use in the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. The first antisense drug molecule is now available for clinical use in Europe and
Saghir Akhtar
exaly   +3 more sources

Cellular delivery of antisense oligonucleotides

European Journal of Pharmaceutics and Biopharmaceutics, 2000
Antisense oligonucleotides can be successfully employed to inhibit specifically gene expression. However, many oligonucleotide classes are polyanions and cannot passively transit the cell membrane. Thus, the use of naked oligonucleotides for antisense purposes poses some rather stringent challenges, and it is not a trivial task to appropriately ...
Irina V Lebedeva, Luba Benimetskaya, C A Stein   +2 more
exaly   +3 more sources

Transdermal delivery of antisense compounds

Advanced Drug Delivery Reviews, 2000
Antisense technology holds tremendous promise for therapeutic applications and the study of gene function. A broadly applicable route of administration that would provide for non-invasive, simple, and convenient delivery is highly desirable. Application of oligonucleotides to the skin may represent a solution to the delivery question for both local ...
R M Brand, Patrick L Iversen
exaly   +3 more sources

The cellular delivery of antisense oligonucleotides and ribozymes

Drug Discovery Today, 2001
The design and development of antisense oligonucleotides and ribozymes for the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. Improvements in oligonucleotide chemistry have led to the synthesis of nucleic acids that are relatively stable in the biological milieu.
Saghir Akhtar
exaly   +3 more sources

Delivery of Antisense Oligonucleotide to the Cornea by Iontophoresis

Antisense and Nucleic Acid Drug Development, 2003
We wished to evaluate the potential of iontophoresis to promote the delivery of antisense oligonucleotides (ODN) directed at the vascular endothelial growth factor (VEGF)-R2 receptor (KDR/Flk) to the cornea of the rat eye. Fluorescence (CY5)-labeled ODNs in phosphate-buffered saline (PBS) (20 microM) were locally administered to rat eyes, and their ...
Berdugo, M, Valamanesh, F, Andrieu, C, Klein, C, Benezra, D, Courtois, Y, Behar-Cohen, F   +6 more
openaire   +3 more sources

Novel non-endocytic delivery of antisense oligonucleotides

Advanced Drug Delivery Reviews, 2000
Antisense oligonucleotides (ONs) have several properties that make them attractive as therapeutic agents. Hybridization of antisense ONs to their complementary nucleic acid sequences by Watson-Crick base pairing is a highly selective and efficient process.
Yon Rojanasakul
exaly   +3 more sources

Transdermal Delivery of Antisense Oligonucleotides

2004
In recent years, antisense oligodeoxynucleotides (ODNs) have emerged as promising biopharmaceutical therapeutics. These agents specifically target genes or gene transcripts involved in pathogenesis. Several clinical trials have demonstrated the therapeutic value and low toxicity of ODNs (1–5).
Rhonda M, Brand, Patrick L, Iversen
openaire   +3 more sources